Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor)

Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor)

Abstract Purpose Bromodomain and extra-terminal domain (BET) inhibitors (BETi) have demonstrated epigenetic modulation capabilities, specifically in transcriptional repression of oncogenic pathways. Preclinical assays suggest that BETi potentially attenuates the PD1/PD-L1 immune checkpoint axis, sup...

Full description

Saved in:
Bibliographic Details
Main Authors: Daniel Marbach, Jurriaan Brouer-Visser, Laura Brennan, Sabine Wilson, Iakov I. Davydov, Nicolas Staedler, José Duarte, Iris Martinez Quetglas, Eveline Nüesch, Marta Cañamero, Evelyne Chesné, George Au-Yeung, Erika Hamilton, Stephanie Lheureux, Debra L. Richardson, Iben Spanggaard, Bruno Gomes, Izolda Franjkovic, Mark DeMario, Martin Kornacker, Katharina Lechner
Format: Article
Language:English
Published: BMC 2025-03-01
Series:BMC Cancer
Subjects:
Bromodomain
BET inhibitor
Immunotherapy
Phase Ib solid tumors
TNBC
Ovarian cancer
Online Access:https://doi.org/10.1186/s12885-025-13851-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-13851-4

Similar Items